Linksbridge

Linksbridge Pharma News continues to track the latest industry news related to the Bundibugyo virus outbreak.

In this week’s highlights, Public Health Vaccines scored funding from BARDA and CEPI to advance Bundibugyo vaccine development, Regeneron’s monoclonal antibody maftivimab joined the list of potential treatments to prioritize for clinical trials, TIB Molbiol shared that it’s offering a Bundibugyo diagnostic to frontline health systems, and more.

Linksbridge Pharma News: this week's highlights Ebola: New vaccine funding and collaborations Global health actors are taking additional steps to fight the Ebola outbreak caused by the Bundibugyo virus in DRC and Uganda, building on measures we covered last week. rVSV jabs win new funds: Massachusetts-based Public Health Vaccines (PHV) said Tuesd

Less than four years after it was selected as the hub of the WHO-led mRNA tech transfer program, Afrigen's mRNA facility in Cape Town has notched GMP certification. But key challenges remain, including ensuring governments procure locally made products even if they're initially more expensive.

This week's highlights cover African vaccine manufacturing, the Ebola outbreak response, shorter regimens for drug-susceptible TB, and more.

Linksbridge Pharma News: this week's highlights Afrigen reaches GMP milestone Afrigen’s mRNA facility in Cape Town has become the first facility on the continent to notch GMP certification, Health Policy Watch reported last week. The development comes less than four years after the company was selected as the hub of the WHO-led mRNA tech transf...

Last week's World Malaria Day generated a flurry of pharma news important to global health, including WHO's prequalification of Coartem Baby (the Novartis/MMV infant antimalarial), India's sign-off on Phase 3 trials of Zydus Lifesciences' oral antimalarial zintrodiazine, Serum Institute of India's licensing deal with Oxford University for a blood-stage vaccine, and more.

Linksbridge Pharma: this week's highlights Coartem Baby wins WHO PQ WHO has prequalified Coartem Baby, the newborn-and-infant antimalarial jointly developed by Novartis and Medicines for Malaria Ventures (MMV). Novartis trumpeted the news last week, just ahead of World Malaria Day.

This week's issue highlights challenges along the path from drug innovation to patient access:

» Gilead's refusal to sell lenacapavir to MSF shows how a manufacturer's access framework can fall short, leaving people who need HIV PrEP without it.

» Meanwhile, efforts to push Merck to commit to generic licensing for its promising oral PrEP candidate before it reaches the market aim to avoid the same post-approval access scramble.

» Antibiotic developer Iterum's collapse demonstrates a different kind of obstacle: even when a drug is approved and available, weak commercial incentives can still choke off access.

Linksbridge Pharma: this week's highlights MSF blasts Gilead over lenacapavir sales Médecins Sans Frontières (MSF) is publicly slamming Gilead for its “outright refusal” to sell Yeztugo (lenacapavir) to the humanitarian organization. In an open letter last week, MSF faulted the drugmaker’s “unconscionable” restrictions on access ...